ArticleExperimental eye research2025
Treatment of nitrogen mustard-induced corneal injury with alpha-melanocyte stimulating hormone.
Article in Experimental eye research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Corneal macrophages and limbal stem cells: emerging roles in ocular surface regeneration.Annals of medicine · 2026Review
- BRD4 inhibition mitigates acute and chronic corneal injury following topical nitrogen mustard exposure.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Current progress in research on ocular injury caused by exposure to vesicants.Progress in retinal and eye research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Nitrogen mustard (NM) exposure leads to severe corneal damage, resulting in persistent corneal inflammation, epithelial damage, endothelial dysfunction, and vision impairment. Effective therapeutic strategies to mitigate these effects remain limited. This study evaluates the protective effects of alpha-melanocyte-stimulating hormone (α-MSH) in a murine model of NM-induced corneal injury. C57BL/6 mice were exposed to NM and treated with systemic α-MSH for 28 days. Clinical assessments, histological analysis, anterior segment optical coherence tomography (AS-OCT), and immunohistochemistry were performed to evaluate corneal integrity, inflammation, and cell survival. α-MSH treatment significantly reduced corneal epitheliopathy, prevented epithelial thinning, and preserved limbal epithelial cell density compared to untreated controls. Central stromal thickness was significantly lower in α-MSH-treated mice, suggesting reduced corneal edema. Endothelial cell morphology was preserved, with higher endothelial cell density, reduced coefficient of variation, and improved hexagonality in treated mice. TUNEL assay demonstrated significantly lower apoptosis in both central and limbal corneal regions at early (day 7) and late (day 28) time points in α-MSH-treated eyes. These findings highlight the cytoprotective and anti-inflammatory effects of α-MSH. By mitigating NM-induced injury, α-MSH preserves corneal structural integrity and function, demonstrating its potential as a therapeutic intervention for mustard gas keratopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.